The study involved 225 adults with moderate to severe non-proliferative diabetic retinopathy (DR) or mild proliferative DR with minimal vision loss. Credit: Africa Studio / Shutterstock.com.

OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops for patients with diabetic retinopathy (DR) failed to meet endpoints.

The trial was designed to evaluate the safety and efficacy of high and low dose of daily topical administration of nesvategrast compared to placebo for 24 weeks.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

This multicentre, randomised, double-masked study involved 225 adults with moderate to severe non-proliferative DR (NPDR) or mild proliferative DR (PDR) with minimal vision loss.

The trial’s primary efficacy endpoint was the percentage of subjects achieving a two-step or greater improvement on the DR Severity Scale (DRSS).

Additional objectives included evaluating the prevention of progression to vision-threatening events, the delay in needing intravitreal injections or laser treatment, and exploratory imaging endpoints.

See Also:

Findings showed that the trial did not meet its primary or key secondary efficacy endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the trial, nesvategrast was found to be safe and well-tolerated, fulfilling its primary safety endpoint.

While the topline data confirmed the treatment’s safety, it did not show a statistically significant improvement in DRSS scores for patients treated with nesvategrast compared to the placebo group.

The treatment also failed to significantly impact the progression of the disease as measured by DRSS.

Nevertheless, a sub-analysis revealed a statistically significant benefit in preventing the onset of vision-threatening events by week 24 in patients with moderately severe to severe NPDR at baseline.

OcuTerra CEO and president Kerrie Brady said: “We are disappointed that the topline data on nesvategrast from our Phase II DR:EAM clinical trial did not demonstrate a statistically significant impact on severity or progression of diabetic retinopathy.

“We plan to review the full dataset from the DR:EAM study to evaluate the future of the nesvategrast programme.”

Last July, the company completed subject enrolment in Phase II DR:EAM trial of OTT166 eye drops.